JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Inclusion Criteria:

• Must have histologically or cytologically confirmed metastatic or locally advancedsolid tumor. Some cohorts must meet specific expression or gene mutation whereindicated

• Sufficient organ function

• Participants must have at least 1 measurable lesion as defined by RECIST v1.1

• Must be able to provide an archived tumor sample

• ECOG performance status score of 0 or 1.

Exclusion Criteria:

• History of cancer that is histologically distinct from the cancers under study

• Active or untreated central nervous system (CNS) metastases

• History of pneumonitis or interstitial lung disease (ILD)

• Has active hepatitis B, hepatitis C infection, HIV

• Any severe and/or uncontrolled medical conditions

• LVEF ≤50%

• QTcF >470 msec